Pipeline / Eight programs
Built to phase gates.
Eight programs across rare disease, oncology, and immunology, all on the same editor platform and the same five phase gates. Nothing advances on narrative; a program advances on data.
The path
Five phases, one discipline.
-
Discovery
18 to 24 months
Target triage and editor design. Tissue models, in-silico address maps, and a go or no-go inside eighteen months.
-
Lead optimization
12 to 18 months
One editor per program. Top clone selected, process development started, and a GMP slot reserved.
-
IND-enabling
12 months
GLP toxicology, whole-genome release data, and the CMC file assembled to specification.
-
Phase 1/2
24 to 36 months
First in human. Safety, biomarker evidence of editing, and dose expansion in the target tissue.
-
Registration
36 months
Pivotal design, market access, and the manufacturing network to supply a single-infusion therapy.
04 / Pipeline
The pipeline.
| Program | Edit | Indication | Modality | Phase | Next readout |
|---|---|---|---|---|---|
| BRD-101 | HbS mutation correction HBB | Sickle cell disease Rare disease | In-vivo editor | Phase 1/2 | Interim data Q2 2027 |
| BRD-301 | G542X stop-codon correction CFTR exon 12 | Cystic fibrosis Rare disease | In-vivo editor | IND-enabling | IND filing Q1 2027 |
| BRD-103 | F9 Padua knock-in F9 exon 8 | Hemophilia B Rare disease | In-vivo editor | Lead optimization | Ph1 start 2028 |
| BRD-202 | TRAC to CD19 CAR knock-in TRAC locus | CD19+ B-cell malignancies Oncology | Ex-vivo cell therapy | Lead optimization | Ph1 start 2028 |
| BRD-201 | Y220C stabilizer potentiation TP53 | TP53-mutant solid tumors Oncology | Editor-potentiator | Discovery | Candidate 2027 |
| BRD-203 | SIRPa knockout armoring SIRPa | Acute myeloid leukemia Oncology | Ex-vivo cell therapy | Discovery | Candidate 2028 |
| BRD-401 | IL-2 locus rheostat edit IL2 promoter | Refractory autoimmunity Immunology | In-vivo editor | Discovery | Candidate 2028 |
| BRD-402 | HLA-E universal cloak edit B2M locus | Allogeneic cell reservoirs Immunology | Ex-vivo cell therapy | Discovery | Candidate 2029 |
All programs investigational. No approved indications. Phases per internal program review, September 2026.
Modes of action